BRISTOL MYERS SQUIBB
- Country
- ๐ซ๐ทFrance
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2011-04-15
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00035568
- Locations
- ๐บ๐ธ
Local Institution, San Antonio, Texas, United States
A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes.
- Conditions
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2011-04-15
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00035542
- Locations
- ๐บ๐ธ
National Institute Of Clinical Research, Los Angeles, California, United States
๐บ๐ธDriscoll Children's Hospital/Division of Medical Education/William Riley, Corpus Christi, Texas, United States
๐บ๐ธMetro Health Medical Center, Cleveland, Ohio, United States
A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen
- Conditions
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00035789
- Locations
- ๐บ๐ธ
Local Investigator, Seattle, Washington, United States
A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2010-12-06
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00035529
- Locations
- ๐บ๐ธ
Local Institution, Madison, Wisconsin, United States
Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2016-09-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 444
- Registration Number
- NCT00035152
- Locations
- ๐บ๐ธ
Hennepin County Medical Center, Minneapolis, Minnesota, United States
๐บ๐ธSiouxland Hematology/Oncology Associates, Sioux City, Iowa, United States
๐บ๐ธWellstar Cobb Hospital, Austell, Georgia, United States
A Trial to Evaluate Epothilone D in Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2002-02-08
- Last Posted Date
- 2009-01-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 45
- Registration Number
- NCT00030173
- Locations
- ๐บ๐ธ
UCLA Medical Center, Los Angeles, California, United States
Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)
- Conditions
- First Posted Date
- 2001-12-21
- Last Posted Date
- 2010-09-13
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00028301
- Locations
- ๐ง๐ช
University Hospital Gent, Gent, Belgium
๐ฆ๐ทCAICI, Rosario Santa Fe, Argentina
๐ง๐ชCHU Saint Pierre, Brussels, Belgium
A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor
- Conditions
- First Posted Date
- 2001-12-11
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 500
- Registration Number
- NCT00028067
- Locations
- ๐น๐ญ
Ramathibodi Hosp, Bangkok, Thailand
๐น๐ญKhonkaen Univ, Khonkaen, Thailand
๐บ๐ธHealth for Life Clinic, Little Rock, Arkansas, United States
Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 500
- Registration Number
- NCT00002429
- Locations
- ๐บ๐ธ
NJCRI, Newark, New Jersey, United States
๐บ๐ธUniv of Texas Southwestern Med Ctr of Dallas, Dallas, Texas, United States
๐จ๐ฆClinique Medicale L'Actuele, Montreal, Quebec, Canada
The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 80
- Registration Number
- NCT00002371
- Locations
- ๐บ๐ธ
Harbor UCLA Med Ctr, Torrance, California, United States
๐บ๐ธSUNY at Stony Brook / Division of Infectious Diseases, Stony Brook, New York, United States
๐จ๐ฆMontreal Gen Hosp / Div of Clin Immuno and Allergy, Montreal, Quebec, Canada